BackOcuphire Pharma Overview

Ocuphire Pharma Other Current Liabilities

Ocuphire Pharma's other current liabilities is $4.9M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$4.92M
74.64% YoYΔ $-14.47M vs prior year quarter

Peer average

Loading

Ocuphire Pharma Other Current Liabilities History

Loading

Ocuphire Pharma vs. peers: Other Current Liabilities Comparison

Loading

Ocuphire Pharma Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Ocuphire Pharma (OCUP) FAQ

Ocuphire Pharma's other current liabilities stands at $4.9M as of March 2026. That compares with $19M in the prior-year period — down 74.6% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ocuphire Pharma reported $4.9M in other current liabilities versus $19M a year earlier — a 74.6% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $19M in the prior-year period — down 74.6% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ocuphire Pharma's other current liabilities evolved across reporting periods, while the comparison chart places OCUP next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Ocuphire Pharma's reading of $4.9M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.